SCHEMBL674281

SCHEMBL674281

CCOC(=O)c1csc(-c2c(Cl)cnn2C)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
ALDH1A1 P00352 2/20 0.51
RAB9A P51151 7/20 0.50
NPC1 O15118 6/20 0.50
POLB P06746 1/20 0.50
PKM P14618 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 3/20 0.47
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
CLK1 P49759 1/20 0.43
EGFR P00533 1/20 0.42
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
HSP90AA1 P07900 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675149 0.82 ALDH1A1 (0.46) MAPTALDH1A1RAB9AGAASMN1; SMN2
SCHEMBL13144514 0.78 MAPT (0.70) MAPTALDH1A1RAB9ANPC1POLB
SCHEMBL674347 0.75 RAB9A (0.55) MAPTALDH1A1RAB9ANPC1POLB
SCHEMBL793051 0.74 RAB9A (0.58) MAPTALDH1A1RAB9ANPC1POLB
SCHEMBL5896297 0.74 RAB9A (0.61) MAPTALDH1A1RAB9ANPC1POLB
SCHEMBL5338937 0.73 RAB9A (0.58) MAPTALDH1A1RAB9ANPC1POLB
SCHEMBL8345149 0.73 RAB9A (0.69) MAPTALDH1A1RAB9ANPC1POLB
SCHEMBL3535303 0.72 PANK3 (0.57) MAPTALDH1A1RAB9ANPC1POLB
SCHEMBL18002724 0.72 RAB9A (0.61) MAPTALDH1A1RAB9ANPC1POLB
SCHEMBL20241724 0.72 MAPT (0.63) MAPTALDH1A1RAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160255-A1 INHIBITORS OF AKT ACTIVITY GLAXOSMITHKLINE LLC 2011-06-30 US disclosed
US-20110160255-A1 INHIBITORS OF AKT ACTIVITY GLAXOSMITHKLINE LLC 2011-06-30 US disclosed
US-20110160255-A1 INHIBITORS OF AKT ACTIVITY GLAXOSMITHKLINE LLC 2011-06-30 US disclosed
EP-2303852-A2 INHIBITORS OF AKT ACTIVITY GlaxoSmithKline LLC (US) 2011-04-06 EP disclosed
WO-2009158374-A2 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160255-A1 INHIBITORS OF AKT ACTIVITY AKT2, AKT1, PIK3CA MAPT 3545/4885ALDH1A1 4692/4885RAB9A 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.